In this context, SIRT1 expression levels were found to be significantly reduced in the skin and dermal fibroblasts of SSc patients, as well as in the lesional skin from mice with bleomycin-induced scleroderma, with SIRT1 activation leading to a mitigation of fibrosis both in vitro and in vivo [13,19]. This evidence concerns the gene SIRT1 and systemic sclerosis.